Patients must meet all of the following inclusion criteria to be eligible for inclusion in
1. Patients diagnosed as relapsed or refractory B-cell precursor lymphoblastic leukemia
2. Evidence of a personally signed and dated informed consent document indicating that
the patient (or a legally acceptable representative) has been informed of all
pertinent aspects of the study.
Patients meeting any of the following criteria will not be included in the study:
1. Any patients who does not agree that Pfizer and companies working with Pfizer use
2. Patients to whom BESPONSA® is contraindicated as per the local labeling.